Study Name Principal Investigator
(BIO101-COVA) Adaptive design phase 2 to 3, randomized, double-blind, multicenter, to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BIO101 in the prevention of the respiratory deterioration in hospitalized patients with COVID-19 pneumonia (severe stage) Islam, Shaheen
(CD12) A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (COVID-19) Islam, Shaheen
(CONGA) COVID-19 Neurological and Molecular Prospective Cohort Study in Georgia Wang, Xiaoling
(EB05) A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Eb05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients with Covid-19 Taskar, Varsha
ACTIV-4C: A multicenter, adaptive, prospective, randomized trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge (Short title: COVID-19 Post-hospital Thrombosis Prevention Study) Vazquez, Jose
FITE19: Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects with COVID-19 (PTC299-VIR-015-COV19) Vazquez, Jose
R10933-10987-COV-2067: A Master Protocol Assessing the Safety, Tolerability and Efficacy of Anti-SPIKE(s) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients with COVID-19 Vazquez, Jose
REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP): COVID-19 (REMAP-COVID) / RCC2116 Vazquez, Jose
SARS2 SeroPrevalence And Respiratory Tract Assessment (SPARTA) Kolhe, Ravindra
The Impact of COVID 19 on Laryngeal Function, Voice, Communication and Quality of Life Postma, Gregory
TL-895-202: A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer Cortes, Jorge